glp-1 receptor agonist and dpp-4 inhibitor combination not recommended It's the first in a class of drugs called inhibitors Molecular Insights into the Potential
Description
GLP-1 also suppresses glucagon release, thus helping maintain blood glucose levels

Y., et al

The FDA has approved certain medications (Victoza, Ozempic, Trulicity) for cardiovascular risk reduction in patients with established cardiovascular disease and type 2 diabetes, and Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who have overweight or obesity

Mishra R, Raj R, Elshimy G, et al

The fact that I made the 7-37 peptide at Mass General, where the clinical studies were done, turned out to be critical

Current Urology Reports, 24 (11), 515525.